AstraZeneca Plc is looking to strengthen its presence in biologics and to rebuild its oncology portfolio as it seeks to reignite growth after a period of patent expirations that have caused sharp declines in both revenue and operating profit. ---Subscribe to MedNous to access this article--- Company News